The C5a Receptor Antagonist PMX205 Ameliorates Experimentally Induced Colitis Associated with Increased IL-4 and IL-10

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2012 Aug 29

PMID 22924972

Citations 24

Authors

U Jain

T M Woodruff

A W Stadnyk

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Anti-complement therapies have not been advanced for treating the inflammatory bowel diseases (IBDs) despite a growing body of evidence that blocking C5a protects against induced colitis in rodents. The purpose of this study was to further build on this evidence by examining the efficacy, mechanism and specificity of a potent, non-competitive and orally active C5a receptor (CD88) antagonist, PMX205, in the dextran sulphate sodium (DSS) model of murine innate colitis.

Experimental Approach: Mice with DSS added to their drinking water were orally administered 100 or 200 μg day(-1) PMX205 in prophylactic and therapeutic regimens. Clinical illness, colon histology and local generation of inflammatory mediators were measured to evaluate the impact of PMX205 on disease.

Key Results: PMX205 significantly prevented DSS-induced colon inflammation in both regimens, associated with lower pro-inflammatory cytokine production and nitrotyrosine staining in colon sections. Additionally, the levels of anti-inflammatory cytokines IL-4 and IL-10 were increased. PMX205 had no significant effect on C5a levels. The beneficial effect of PMX205 was seen in two strains of mice of differing sensitivities to DSS inflammation, but was inactive in mice lacking CD88.

Conclusions And Implications: Pharmacological inhibition of C5a activity by PMX205 is efficacious in preventing DSS-induced colitis, providing further evidence that targeting CD88 in IBD patients could be a valuable therapeutic option.

Citing Articles

Multi-Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation.

Freire Haddad H, Roe E, Xie Fu V, Curvino E, Collier J Adv Healthc Mater. 2024; 14(1):e2402546.

PMID: 39475070 PMC: 11695164. DOI: 10.1002/adhm.202402546.

Fibroblast growth factor receptor 4 deficiency in macrophages aggravates experimental colitis by promoting M1-polarization.

Shen L, Wang C, Ren R, Liu X, Zhou D, Chen Y Inflamm Res. 2024; 73(9):1493-1510.

PMID: 38981913 DOI: 10.1007/s00011-024-01910-8.

Complement System Inhibitory Drugs in a Zebrafish () Model: Computational Modeling.

Fernandes D, Tambourgi D Int J Mol Sci. 2023; 24(18).

PMID: 37762197 PMC: 10530807. DOI: 10.3390/ijms241813895.

GNA12 regulates C5a-induced migration by downregulating C5aR1-PLCβ2-PI3K-AKT-ERK1/2 signaling.

Yu H, Liu Z Biophys Rep. 2023; 9(1):33-44.

PMID: 37426201 PMC: 10323775. DOI: 10.52601/bpr.2023.230001.

Increased Levels of C5a in Gingival Crevicular Fluid and Saliva of Patients with Periodontal Disease.

Bhalla S, Shaju A, Figueredo C, Miranda L Pathogens. 2022; 11(9).

PMID: 36145415 PMC: 9503606. DOI: 10.3390/pathogens11090983.

References

Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann H . Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol. 2005; 174(2):783-9. DOI: 10.4049/jimmunol.174.2.783. View

Hawlisch H, Wills-Karp M, Karp C, Kohl J . The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol. 2004; 41(2-3):123-31. DOI: 10.1016/j.molimm.2004.03.019. View

Stillie R, Stadnyk A . Role of TNF receptors, TNFR1 and TNFR2, in dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 2009; 15(10):1515-25. DOI: 10.1002/ibd.20951. View

Wirtz S, Neufert C, Weigmann B, Neurath M . Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2(3):541-6. DOI: 10.1038/nprot.2007.41. View

Fonseca M, Ager R, Chu S, Yazan O, Sanderson S, LaFerla F . Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009; 183(2):1375-83. PMC: 4067320. DOI: 10.4049/jimmunol.0901005. View

Pavlovski D, Thundyil J, Monk P, Wetsel R, Taylor S, Woodruff T . Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 2012; 26(9):3680-90. DOI: 10.1096/fj.11-202382. View

Monk P, Scola A, Madala P, Fairlie D . Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007; 152(4):429-48. PMC: 2050825. DOI: 10.1038/sj.bjp.0707332. View

Arumugam T, Woodruff T, Stocks S, Proctor L, Pollitt S, Shiels I . Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol. 2004; 40(6):934-41. DOI: 10.1016/j.jhep.2004.02.017. View

Hanauer S . Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2005; 12 Suppl 1:S3-9. DOI: 10.1097/01.mib.0000195385.19268.68. View

10.

Satsangi J, Morecroft J, Shah N, Nimmo E . Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol. 2003; 17(1):3-18. DOI: 10.1053/bega.2002.0349. View

11.

Czermak B, Sarma V, Pierson C, Warner R, Huber-Lang M, Bless N . Protective effects of C5a blockade in sepsis. Nat Med. 1999; 5(7):788-92. DOI: 10.1038/10512. View

12.

Woodruff T, Nandakumar K, Tedesco F . Inhibiting the C5-C5a receptor axis. Mol Immunol. 2011; 48(14):1631-42. DOI: 10.1016/j.molimm.2011.04.014. View

13.

Hunter M, Wang A, Parhar K, Johnston M, van Rooijen N, Beck P . In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology. 2010; 138(4):1395-405. DOI: 10.1053/j.gastro.2009.12.041. View

14.

Stevceva L, Pavli P, Husband A, Doe W . The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it. BMC Clin Pathol. 2001; 1(1):3. PMC: 57007. DOI: 10.1186/1472-6890-1-3. View

15.

Woodruff T, Crane J, Proctor L, Buller K, Shek A, Vos K . Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 2006; 20(9):1407-17. DOI: 10.1096/fj.05-5814com. View

16.

Woodruff T, Pollitt S, Proctor L, Stocks S, Manthey H, Williams H . Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther. 2005; 314(2):811-7. DOI: 10.1124/jpet.105.086835. View

17.

Snyderman R, Pike M, McCarley D, Lang L . Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity. Infect Immun. 1975; 11(3):488-92. PMC: 415091. DOI: 10.1128/iai.11.3.488-492.1975. View

18.

Discipio R, Schraufstatter I, Sikora L, Zuraw B, Sriramarao P . C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils. Int Immunopharmacol. 2006; 6(7):1109-18. DOI: 10.1016/j.intimp.2006.02.006. View

19.

Alexander S, Mathie A, Peters J . Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol. 2011; 164 Suppl 1:S1-324. PMC: 3315626. DOI: 10.1111/j.1476-5381.2011.01649_1.x. View

20.

Tsuji R, Kawikova I, Ramabhadran R, Taub D, Hugli T, Gerard C . Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol. 2000; 165(3):1588-98. DOI: 10.4049/jimmunol.165.3.1588. View